Slingshot members are tracking this event:

Gilead Sciences (GILD) plan to fully enroll Phase 3 STELLAR trial for nonalcoholic steatohepatitis (NASH) evaluating selonsertib in treating F3 fibrosis by first half of 2018

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
GILD Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nash Fibrosis, Selonsertib, Phase 3, Stellar